Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Pliant Therapeutics stock
Learn how to easily invest in Pliant Therapeutics stock.
Pliant Therapeutics Inc is a biotechnology business based in the US. Pliant Therapeutics shares (PLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Pliant Therapeutics employs 90 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Pliant Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – PLRX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Pliant Therapeutics stock price (NASDAQ: PLRX)Use our graph to track the performance of PLRX stocks over time.
Pliant Therapeutics shares at a glance
|Latest market close||$12.68|
|52-week range||$11.28 - $43.92|
|50-day moving average||$14.67|
|200-day moving average||$22.15|
|Wall St. target price||$46.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.57|
Buy Pliant Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Pliant Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Pliant Therapeutics price performance over time
|1 week (2022-01-12)||0.96%|
|1 month (2021-12-17)||-17.98%|
|3 months (2021-10-19)||-25.63%|
|6 months (2021-07-19)||-49.60%|
|1 year (2021-01-19)||-51.75%|
|2 years (2020-01-15)||N/A|
|3 years (2019-01-15)||N/A|
|5 years (2017-01-15)||N/A|
Is Pliant Therapeutics stock undervalued or overvalued?
Valuing Pliant Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pliant Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pliant Therapeutics's EBITDA
Pliant Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $20.8 million.
The EBITDA is a measure of a Pliant Therapeutics's overall financial performance and is widely used to measure a its profitability.
Pliant Therapeutics financials
|Revenue TTM||$10 million|
|Gross profit TTM||$41.8 million|
|Return on assets TTM||-21.03%|
|Return on equity TTM||-35.24%|
|Market capitalisation||$457 million|
TTM: trailing 12 months
Pliant Therapeutics share dividends
We're not expecting Pliant Therapeutics to pay a dividend over the next 12 months.
Pliant Therapeutics overview
Pliant Therapeutics, Inc. , a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.
Pliant Therapeutics in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones
Frequently asked questionsWhat percentage of Pliant Therapeutics is owned by insiders or institutions?
Currently 9.456% of Pliant Therapeutics shares are held by insiders and 84.827% by institutions. How many people work for Pliant Therapeutics?
Latest data suggests 90 work at Pliant Therapeutics. When does the fiscal year end for Pliant Therapeutics?
Pliant Therapeutics's fiscal year ends in December. Where is Pliant Therapeutics based?
Pliant Therapeutics's address is: 260 Littlefield Avenue, South San Francisco, CA, United States, 94080 What is Pliant Therapeutics's ISIN number?
Pliant Therapeutics's international securities identification number is: US7291391057 What is Pliant Therapeutics's CUSIP number?
Pliant Therapeutics's Committee on Uniform Securities Identification Procedures number is: 69912C105
More guides on Finder
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
How to buy Specialty Building Products (SBP) stock when it goes public
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Ask an Expert